A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease

Pfeffer, Marc A., Burdmann, Emmanuel A., Chen, Chao-Yin, Cooper, Mark E., de Zeeuw, Dick, Eckardt, Kai-Uwe, Feyzi, Jan M., Ivanovich, Peter, Kewalramani, Reshma, Levey, Andrew S., Lewis, Eldrin F., McGill, Janet B., McMurray, John J.V., Parfrey, Patrick, Parving, Hans-Henrik, Remuzzi, Giuseppe, Singh, Ajay K., Solomon, Scott D., Toto, Robert·2009·New England Journal of Medicine
DOI 10.1056/nejmoa0907845

Cited by (1,000)

Items 401–500 of 1,000

  1. Ferumoxytol: a silver lining in the treatment of anemia of chronic kidney disease or another dark cloud?
    Amy Barton Pai, Garba · 2012 · Journal of Blood Medicine
  2. High doses of epoetin do not lower mortality and cardiovascular risk among elderly hemodialysis patients with diabetes
    Yi Zhang, Mae Thamer, James S. Kaufman, Dennis J. Cotter, Miguel Ángel Hernán · 2011 · Kidney International
  3. Erythropoiesis-stimulating agents in chronic kidney disease: What have we learned in 25 years?
    Szu‐Chun Hung, Yao‐Ping Lin, Der‐Cherng Tarng · 2013 · Journal of the Formosan Medical Association
  4. Association of ESA hypo-responsiveness and haemoglobin variability with mortality in haemodialysis patients
    Alexander Kainz, Bernd Mayer, Reinhard Kramar, Rainer W. Oberbauer · 2010 · Nephrology Dialysis Transplantation
  5. The Labile Side of Iron Supplementation in CKD
    Itzchak N. Slotki, Zvi Ioav Cabantchik · 2015 · Journal of the American Society of Nephrology
  6. Therapeutic Strategies for Heart Failure in Cardiorenal Syndromes
    Andrew A. House, Mikko Haapio, Johan P.E. Lassus, Rinaldo Bellomo, Claudio Ronco · 2010 · American Journal of Kidney Diseases
  7. Canadian Society of Nephrology Commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD–Mineral and Bone Disorder (CKD-MBD)
    Braden Manns, Anthony B. Hodsman, Deborah Lynn Zimmerman, David C. Mendelssohn, Steven Soroka, Christopher T. Chan, Kailash K Jindal, Scott W Klarenbach · 2010 · American Journal of Kidney Diseases
  8. Current and emerging treatment options for the elderly patient with chronic kidney disease
    Robert Gordon Fassett · 2014 · Clinical Interventions in Aging
  9. Non-transferrin bound iron, cytokine activation and intracellular reactive oxygen species generation in hemodialysis patients receiving intravenous iron dextran or iron sucrose
    Amy Barton Pai, Todd A. Conner, Charles R. McQuade, Jonathan Olp, Paul Hicks · 2011 · BioMetals
  10. Parenteral iron formulations differentially affect MCP-1, HO-1, and NGAL gene expression and renal responses to injury
    Ali C.M. Johnson, Kirsten Becker, Richard A. Zager · 2010 · American Journal of Physiology-Renal Physiology
  11. Mortality Associated with Dose Response of Erythropoiesis-Stimulating Agents in Hemodialysis versus Peritoneal Dialysis Patients
    Uyen Duong, Kamyar Kalantar‐Zadeh, Miklos Zsolt Molnar, Joshua J. Zaritsky, Isaac Teitelbaum, Csaba Pal Kovesdy, Rajnish Mehrotra · 2012 · American Journal of Nephrology
  12. Cardiorenal Syndrome and the Role of the Bone-Mineral Axis and Anemia
    David M. Charytan, Steven N. Fishbane, Jolanta Małyszko, Peter Andrew McCullough, David J.A. Goldsmith · 2015 · American Journal of Kidney Diseases
  13. Erythropoietin treatment in patients with acute myocardial infarction: A meta-analysis of randomized controlled trials
    Dengfeng Gao, Ning Ning, Xiaolin Niu, Yinhu Dang, Xin Dong, Jin jia Wei, Canzhan Zhu · 2012 · American Heart Journal
  14. The Cardiorenal Syndrome: A Review
    Benoy Nalin Shah, Kim Greaves · 2010 · International Journal of Nephrology
  15. Association of Hemoglobin and Survival in Peritoneal Dialysis Patients
    Miklos Zsolt Molnar, Rajnish Mehrotra, Uyen Duong, Csaba Pal Kovesdy, Kamyar Kalantar‐Zadeh · 2011 · Clinical Journal of the American Society of Nephrology
  16. Association of Erythropoietin Dose and Route of Administration with Clinical Outcomes for Patients on Hemodialysis in the United States
    Daniel G. Wright, Elizabeth C. Wright, Andrew S. Narva, Constance Tom Noguchi, Paul W. Eggers · 2015 · Clinical Journal of the American Society of Nephrology
  17. Preoperative Anemia in Cardiac Operation: Does Hemoglobin Tell the Whole Story?
    Lu Dai, Stephanie L. Mick, Keith R. McCrae, Penny L. Houghtaling, Joseph F. Sabik, Eugene H. Blackstone, Colleen Gorman Koch · 2017 · The Annals of Thoracic Surgery
  18. Left Ventricular Assist Devices, Kidney Disease, and Dialysis
    Bethany Angela Roehm, Amanda Ruth Vest, Daniel E. Weiner · 2017 · American Journal of Kidney Diseases
  19. Erythropoiesis-Stimulating Agents in the Management of Anemia in Chronic Kidney Disease or Cancer: A Historical Perspective
    Matti Aapro, Pere Gascón, Kashyap B Patel, George M. Rodgers, Selwyn Fung, Luiz H. Arantes, Jay B. Wish · 2019 · Frontiers in Pharmacology
  20. Promises and Pitfalls in Erythopoietin-Mediated Tissue Protection: Are Nonerythropoietic Derivatives a Way Forward?
    Carla Cerami Hand, Michael L. Brines · 2011 · Journal of Investigative Medicine
  21. Thresholds of iron markers for iron deficiency erythropoiesis—finding of the Japanese nationwide dialysis registry
    Takayuki Hamano, Naohiko Fujii, Terumasa Hayashi, Hiroyasu Yamamoto, Kunitoshi Iseki, Yoshiharu Tsubakihara · 2015 · Kidney International Supplements
  22. Should we reconsider iron administration based on prevailing ferritin and hepcidin concentrations?
    Takeshi Nakanishi, Takahiro Kuragano, Shoji Kaibe, Yasuyuki Nagasawa, Yukiko Hasuike · 2012 · Clinical and Experimental Nephrology
  23. Unmet need in diabetic nephropathy: failed drugs or trials?
    Dick de Zeeuw, Hiddo J.L. Heerspink · 2016 · The Lancet Diabetes & Endocrinology
  24. Anemia in patients of diabetic kidney disease
    Shang-Feng Tsai, Der‐Cherng Tarng · 2019 · Journal of the Chinese Medical Association
  25. Prevention and treatment of stroke in patients with chronic kidney disease: an overview of evidence and current guidelines
    Dearbhla Kelly, Peter Malcolm Rothwell · 2019 · Kidney International
  26. How I treat renal anemia
    Steven N. Fishbane, Daniel W. Coyne · 2020 · Blood
  27. Novel drugs and intervention strategies for the treatment of chronic kidney disease
    Hiddo J.L. Heerspink, Dick de Zeeuw · 2013 · British Journal of Clinical Pharmacology
  28. Increased Risk of Stroke with Darbepoetin Alfa in Anaemic Heart Failure Patients with Diabetes and Chronic Kidney Disease
    Natalie Ann Bello, Eldrin Foster Lewis, Akshay Suvas Desai, Inder S. Anand, Henry Krum, John J.V. McMurray, Kurt A. Olson, Scott David Solomon, Karl B Swedberg, Dirk Jan van Veldhuisen et al. · 2015 · European Journal of Heart Failure
  29. Mechanistic and Clinical Comparison of the Erythropoietic Effects of SGLT2 Inhibitors and Prolyl Hydroxylase Inhibitors in Patients with Chronic Kidney Disease and Renal Anemia
    Milton Packer · 2023 · American Journal of Nephrology
  30. Onco-nephrology: an appraisal of the cancer and chronic kidney disease links
    Hassan Izzedine, Mark Anthony Perazella · 2015 · Nephrology Dialysis Transplantation
  31. Renal Association Clinical Practice Guideline on Anaemia of Chronic Kidney Disease
    Ashraf I. Mikhail, Rajesh Shrivastava, Donald Richardson · 2011 · Nephron Clinical Practice
  32. Associations of Conventional Echocardiographic Measures with Incident Heart Failure and Mortality: The Chronic Renal Insufficiency Cohort
    Ruth F. Dubin, Rajat Deo, Nisha Bansal, Amanda Hyre Anderson, Peter H Yang, Alan S. Go, Martin Gerard Keane, Ray R. Townsend, Anna C. Porter, Matthew Jay Budoff et al. · 2016 · Clinical Journal of the American Society of Nephrology
  33. The ASCEND-NHQ randomized trial found positive effects of daprodustat on hemoglobin and quality of life in patients with non-dialysis chronic kidney disease
    Kirsten L. Johansen, Alexander R. Cobitz, Ajay K. Singh, Iain C. Macdougall, Renato D. Lópes, Gregorio T. Obrador, Csaba Pal Kovesdy, Rubeen Israni, Vivekanand Jha, Tony Okoro et al. · 2023 · Kidney International
  34. Targeting EPO and EPO receptor pathways in anemia and dysregulated erythropoiesis
    Nicole Rainville, Edward Jachimowicz, Don M. Wojchowski · 2015 · Expert Opinion on Therapeutic Targets
  35. Low Hemoglobin Levels and Hypo‐Responsiveness to Erythropoiesis‐Stimulating Agent Associated With Poor Survival in Incident J apanese Hemodialysis Patients
    Tadao Akizawa, Akira Saitō, Fumitake Gejyo, Masashi Suzuki, Yoshiki Nishizawà, Yasuhiko Tomino, Yoshiharu Tsubakihara, Takashi Akiba, Hideki Hirakata, Yuzo Watanabe et al. · 2014 · Therapeutic Apheresis and Dialysis
  36. How important is transfusion avoidance in 2013?
    Iain C. Macdougall, Gregorio T. Obrador · 2013 · Nephrology Dialysis Transplantation
  37. The New FDA Labeling for ESA—Implications for Patients and Providers
    Braden Manns, Marcello A. Tonelli · 2012 · Clinical Journal of the American Society of Nephrology
  38. Coronary Artery Disease Is a Predictor of Progression to Dialysis in Patients With Chronic Kidney Disease, Type 2 Diabetes Mellitus, and Anemia: An Analysis of the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)
    Marwa Sabe, Brian Lee Claggett, Emmanuel A. Burdmann, Akshay Suvas Desai, Peter T. Ivanovich, Reshma Kewalramani, Eldrin Foster Lewis, John J.V. McMurray, Kurt A. Olson, Patrick S. Parfrey et al. · 2016 · Journal of the American Heart Association
  39. Roxadustat in the treatment of anaemia in chronic kidney disease
    Lucia Del Vecchio, Francesco Locatelli · 2017 · Expert Opinion on Investigational Drugs
  40. The Use of Erythropoiesis-Stimulating Agents in Patients With CKD and Cancer: A Clinical Approach
    Sumeska Thavarajah, Michael Jin Choi · 2019 · American Journal of Kidney Diseases
  41. Drug-Induced Hypertension
    Matthew C. Foy, Joban Vaishnav, Christopher John Sperati · 2019 · Endocrinology and Metabolism Clinics of North America
  42. Hepcidin as a predictive factor and therapeutic target in erythropoiesis-stimulating agent treatment for anemia of chronic disease in rats
    Theurl, M., Nairz, M., Schroll, A., Sonnweber, T., Asshoff, M., Haschka, D., Seifert, M., Willenbacher, W., Wilflingseder, D., Posch, W. et al. · 2014 · Haematologica
  43. Inflammation and Erythropoiesis-Stimulating Agent Response in Hemodialysis Patients: A Self-matched Longitudinal Study of Anemia Management in the Dialysis Outcomes and Practice Patterns Study (DOPPS)
    Angelo Karaboyas, Hal Morgenstern, Nancy L. Fleischer, Raymond Camille Vanholder, Nafeesa N Dhalwani, Elke Schäeffner, Douglas Earl Schaubel, Tadao Akizawa, Glen James, Marvin V. Sinsakul et al. · 2020 · Kidney Medicine
  44. Updates on Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in the Treatment of Renal Anemia
    Jing Li, Volker H. Haase, Chuan‐Ming Hao · 2022 · Kidney Diseases
  45. Role of Uremic Toxins in Erythropoiesis-Stimulating Agent Resistance in Chronic Kidney Disease and Dialysis Patients
    Masaomi Nangaku, Imari Mimura, Junna Yamaguchi, Yoshiki Higashijima, Takehiko Wada, Tetsuhiro Tanaka · 2014 · Journal of Renal Nutrition
  46. Three Times Weekly Dosing of Daprodustat versus Conventional Epoetin for Treatment of Anemia in Hemodialysis Patients
    Daniel W. Coyne, Ajay K. Singh, Renato D. Lópes, Christine K. Bailey, Tara L. Dimino, Chun Huang, Jeffrey J. Connaire, Anjay Rastogi, Sung-Gyun Kim, Marcelo Orías et al. · 2022 · Clinical Journal of the American Society of Nephrology
  47. Prevalence and Management of Anaemia in Renal Transplant Recipients: Data from Ten European Centres
    Miklos Zsolt Molnar, István Mucsi, Iain C. Macdougall, James Ernest Marsh, Magdi M. Yaqoob, John Main, Aisling E. Courtney, D. J. FOGARTY, Ashraf I. Mikhail, Gabriel J. Choukroun et al. · 2010 · Nephron Clinical Practice
  48. Impact of Erythropoiesis-Stimulating Agents on Morbidity and Mortality in Patients with Heart Failure: An Updated, Post-TREAT Meta-Analysis
    Akshay Suvas Desai, Eldrin Foster Lewis, Scott David Solomon, John J.V. McMurray, Marc A. Pfeffer · 2010 · European Journal of Heart Failure
  49. Blood disorders after kidney transplantation
    Roman Reindl‐Schwaighofer, Rainer W. Oberbauer · 2013 · Transplantation Reviews
  50. Searching for molecular hypoxia sensors among oxygen-dependent enzymes
    Li Li, Susan Q. Shen, Philip E. Bickler, Matthew P. Jacobson, Lani F. Wu, Steven J. Altschuler · 2023 · eLife
  51. Safety of medical therapy in patients with chronic kidney disease and end-stage renal disease
    Matthew R. Weir, Jeffrey Craig Fink · 2014 · Current Opinion in Nephrology & Hypertension
  52. Rationale, Design, and Baseline Characteristics of ARTS-DN: A Randomized Study to Assess the Safety and Efficacy of Finerenone in Patients with Type 2 Diabetes Mellitus and a Clinical Diagnosis of Diabetic Nephropathy
    Luis Miguel Ruilope, Rajiv Agarwal, Juliana C.N. Chan, Mark Emmanuel Cooper, Ron T. Gansevoort, Hermann G. Haller, Giuseppe Remuzzi, Peter R Rossing, Roland Erich Schmieder, Christina Nowack et al. · 2014 · American Journal of Nephrology
  53. Hepcidin and risk of anemia in CKD: a cross-sectional and longitudinal analysis in the CKiD cohort
    Meredith A. Atkinson, Ji Young Kim, Cindy N. Roy, Bradley A. Warady, Colin Thomas White, Susan L. Furth · 2014 · Pediatric Nephrology
  54. The FIND-CKD study—a randomized controlled trial of intravenous iron versus oral iron in non-dialysis chronic kidney disease patients: background and rationale
    Iain C. Macdougall, Andreas H. Bock, Fernando Carrera, Kai‐Uwe Eckardt, Sandrine Gaillard, David Van Wyck, Bernard Roubert, Timothy Cushway, Simon D. Roger, on Behalf of the FIND-CKD Study Investigators · 2013 · Nephrology Dialysis Transplantation
  55. The greatly misunderstood erythropoietin resistance index and the case for a new responsiveness measure
    Yossi Chait, Sahir Kalim, Joseph Horowitz, C.V. Hollot, Elizabeth D. Ankers, Michael J. Germain, Ravi Thadhani · 2016 · Hemodialysis International
  56. The Future of Clinical Trials in Cardiovascular Medicine
    Scott David Solomon, Marc Alan Pfeffer · 2016 · Circulation
  57. C-Reactive Protein and Risk of ESRD: Results From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)
    Finnian R. Mc Causland, Brian Lee Claggett, Emmanuel A. Burdmann, Kai‐Uwe Eckardt, Reshma Kewalramani, Andrew S. Levey, John J.V. McMurray, Patrick S. Parfrey, Giuseppe Remuzzi, Ajay K. Singh et al. · 2016 · American Journal of Kidney Diseases
  58. Intravenous iron and erythropoiesis‐stimulating agents in haemodialysis: A systematic review and meta‐analysis
    Simon D. Roger, Martin Tio, Hyeong Cheon Park, Hui Lin Choong, Bak Leong Goh, Timothy Cushway, Vanessa Stevens, Iain C. Macdougall · 2016 · Nephrology
  59. Treatment of anemia in difficult-to-manage patients with chronic kidney disease
    Ritesh Raichoudhury, Bruce Spinowitz · 2021 · Kidney International Supplements
  60. Quality of Life in Dialysis Patients: A Retrospective Cohort Study
    Natascha J.H. Broers, Len A. Usvyat, Jeroen Peter Kooman, Frank M. VAN DER SANDE, Eduardo Lacson, Peter Kotanko, Franklin W. Maddux · 2015 · The Nephron journals/Nephron journals
  61. The case for intervention bias in the practice of medicine.
    Andrew Foy, Edward John Filippone · 2013 · Europe PMC (PubMed Central)
  62. Red blood cell transfusion use in patients with chronic kidney disease
    Karminder Gill, Paul Muntner, Richard A. Lafayette, Jeffrey Petersen, Jeffrey Craig Fink, David T. Gilbertson, Brian D. Bradbury · 2013 · Nephrology Dialysis Transplantation
  63. Age and anemia management: relationship of hemoglobin levels with mortality might differ between elderly and nonelderly hemodialysis patients
    Norio Hanafusa, Takanobu Nomura, Takeshi Hasegawa, Masaomi Nangaku · 2014 · Nephrology Dialysis Transplantation
  64. Chapter 5: Referral to specialists and models of care
    2012 · Kidney International Supplements
  65. Novel Derivative of Bardoxolone Methyl Improves Safety for the Treatment of Diabetic Nephropathy
    Huang, Zhangjian, Mou, Yi, Xu, Xiaojun, Zhao, Di, Lai, Yisheng, Xu, Yuwen, Chen, Cen, Li, Ping, Peng, Sixun, Tian, Jide et al. · 2017 · Journal of Medicinal Chemistry
  66. Erythropoietic Stimulating Agents and Quality of a Patient’s Life
    Alan S. Kliger, Steven N. Fishbane, Fredric O. Finkelstein · 2012 · Clinical Journal of the American Society of Nephrology
  67. Anemia in chronic kidney disease
    Maria Amélia Aguiar Hazin · 2020 · Revista da Associação Médica Brasileira
  68. A real-world longitudinal study of anemia management in non-dialysis-dependent chronic kidney disease patients: a multinational analysis of CKDopps
    Marcelo Barreto Lopes, Charlotte Tu, Jarcy Zee, Murilo Henrique Guedes, Ronald L. Pisoni, Bruce M. Robinson, Bryce Stephen Foote, Katarina Hedman, Glen James, Antonio Alberto Lopes et al. · 2021 · Scientific Reports
  69. Hypoxia-Inducible Factor–Prolyl Hydroxyl Domain Inhibitors: From Theoretical Superiority to Clinical Noninferiority Compared with Current ESAs?
    Francesco Locatelli, Lucia Del Vecchio · 2022 · Journal of the American Society of Nephrology
  70. G‐Estimation and Artificial Censoring: Problems, Challenges, and Applications
    Marshall M. Joffe, Wei Peter Yang, Harold I. Feldman · 2011 · Biometrics
  71. Proteinuria as a surrogate end point—more data are needed
    Aliza Thompson · 2012 · Nature Reviews Nephrology
  72. A Randomized, Placebo-Controlled Trial of Pentoxifylline on Erythropoiesis-Stimulating Agent Hyporesponsiveness in Anemic Patients With CKD: The Handling Erythropoietin Resistance With Oxpentifylline (HERO) Trial
    David Wayne Johnson, Elaine M. Pascoe, Sunil V. Badve, Kim Dalziel, Alan Cass, Philip Clarke, Paolo Ferrari, Stephen Peter McDonald, Alicia T. Morrish, Eugenie Pedagogos et al. · 2014 · American Journal of Kidney Diseases
  73. Advancements in anemias related to chronic conditions
    Gian Cesare Guidi, Clara Lechi Santonastaso · 2010 · Clinical Chemistry and Laboratory Medicine (CCLM)
  74. Iron dosing in kidney disease: inconsistency of evidence and clinical practice
    A.E. Gaweda, Yelena Z. Ginzburg, Yossi Chait, Michael J. Germain, George R. Aronoff, Eliezer A. Rachmilewitz · 2014 · Nephrology Dialysis Transplantation
  75. HIF Activation Against CVD in CKD: Novel Treatment Opportunities
    Tetsuhiro Tanaka, Kai‐Uwe Eckardt · 2018 · Seminars in Nephrology
  76. Clinical and Economic Outcomes of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Post-Bundling Era
    Borut Čižman, Helen T. Smith, Rodrigo Refoios Camejo, Linda Casillas, Harjeet Dhillon, Fan Mu, Eric Qiong Wu, Jipan Xie, Peter R. Zuckerman, Daniel W. Coyne · 2020 · Kidney Medicine
  77. Prevalence of anaemia and its clinical management in patients with stages 3-5 chronic kidney disease not on dialysis in Catalonia: MICENAS I study.
    Aleix Cases, Alberto Martínez‐Castelao, Joan Fort, J Bonal-Bastons, Ruiz Mp, Martí Vallès-Prats, Elisabet Coll Piera, Josep Maria Galcerán Gui · 2014 · PubMed
  78. An Economic Evaluation of Erythropoiesis-Stimulating Agents in CKD
    Fiona M Clement, Scott W Klarenbach, Marcello A. Tonelli, Natasha Wiebe, Brenda R. Hemmelgarn, Braden Manns · 2010 · American Journal of Kidney Diseases
  79. Prevention of cardio-renal syndromes: workgroup statements from the 7th ADQI Consensus Conference
    Peter Andrew McCullough, Mikko Haapio, Sunil V. Mankad, Nereo Zamperetti, Barry M. Massie, Rinaldo Bellomo, Tomás Berl, Stefan D. Anker, Inder S. Anand, Nadia Aspromonte et al. · 2010 · Nephrology Dialysis Transplantation
  80. Comparing the Effectiveness of Dynamic Treatment Strategies Using Electronic Health Records: An Application of the Parametric g‐Formula to Anemia Management Strategies
    Yi Zhang, Jessica G. Young, Mae Thamer, Miguel Ángel Hernán · 2017 · Health Services Research
  81. References
    2012 · Kidney International Supplements
  82. RETRACTED: Pooled Analysis of Roxadustat for Anemia in Patients With Kidney Failure Incident to Dialysis
    Robert Provenzano, Steven N. Fishbane, Lynda Anne M. Szczech, Robert Leong, Khalil G. Saikali, Ming Zhong, Tyson T. Lee, Mark T. Houser, Lars Frison, John Houghton et al. · 2020 · Kidney International Reports · Retracted
  83. Prognostic implications of anemia with or without chronic kidney disease in patients undergoing elective percutaneous coronary intervention
    Yuichiro Kitai, Neiko Ozasa, Takeshi Morimoto, Bingyuan Bao, Yutaka Furukawa, Yoshihisa Nakagawa, Kazushige Kadota, Motoko Yanagita, Satoshi Shizuta, Takeshi Kimura · 2013 · International Journal of Cardiology
  84. Indoxyl Sulfate Counteracts Endothelial Effects of Erythropoietin Through Suppression of Akt Phosphorylation
    Yelixiati Adelibieke, Hidehisa Shimizu, Shinichi Saito, Roumyana Mironova, Toshimitsu Niwa · 2013 · Circulation Journal
  85. Aldosterone blockade in chronic kidney disease: can it improve outcome?
    Robert D. Toto · 2010 · Current Opinion in Nephrology & Hypertension
  86. Effect of intravenous iron use on hospitalizations in patients undergoing hemodialysis: a comparative effectiveness analysis from the DEcIDE-ESRD study
    Navdeep Tangri, Dana C. Miskulin, Jing Zhou, Karen Bandeen-Roche, Wieneke Marleen Michels, Patti L. Ephraim, Aidan McDermott, Deidra C. Crews, Julia J. Scialla, Stephen M. Sozio et al. · 2014 · Nephrology Dialysis Transplantation
  87. Diagnostik und Therapie der chronischen Nierenerkrankung
    Matthias Girndt · 2017 · Der Internist
  88. A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs?
    Wendy L. St. Peter, Lori D Wazny, Eric D. Weinhandl, Katie E. Cardone, Joanna Q. Hudson · 2017 · Drugs
  89. Phosphate-Binder Use in US Dialysis Patients: Prevalence, Costs, Evidence, and Policies
    Wendy L. St. Peter, Lori D Wazny, Eric D. Weinhandl · 2017 · American Journal of Kidney Diseases
  90. Investigational hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) for the treatment of anemia associated with chronic kidney disease
    Lucia Del Vecchio, Francesco Locatelli · 2018 · Expert Opinion on Investigational Drugs
  91. Association of Anemia and Iron Parameters With Mortality Among Patients Undergoing Prevalent Hemodialysis in Taiwan: The AIM‐HD Study
    Ko‐Lin Kuo, Szu‐Chun Hung, Wei‐Cheng Tseng, Ming‐Tsun Tsai, Jia‐Sin Liu, Ming‐Huang Lin, Chih‐Cheng Hsu, Der‐Cherng Tarng, the Taiwan Society of Nephrology Renal Registry Data System, Shuo‐Ming Ou et al. · 2018 · Journal of the American Heart Association
  92. How I treat anemia in heart failure
    Inder S. Anand, Pankaj Gupta · 2020 · Blood
  93. Safety and efficacy of erythropoietin for the treatment of patients with optic neuritis (TONE): a randomised, double-blind, multicentre, placebo-controlled study
    Wolf Alexander Lagrèze, Sebastian Küchlin, Gabriele Ihorst, Birgit Grotejohann, Flemming Beisse, Martin Volkmann, Sven P. Heinrich, Philipp Albrecht, Judith Ungewiß, Michael Wörner et al. · 2021 · The Lancet Neurology
  94. Phosphate binders for the treatment of chronic kidney disease: role of iron oxyhydroxide
    Valeria Cernaro, Domenico Santoro, Antonio Lacquaniti, Giuseppe Costantino, Luca Visconti, Antoine Buemi, Michele Buemi · 2016 · International Journal of Nephrology and Renovascular Disease
  95. Early Trends From the Study to Evaluate the Prospective Payment System Impact on Small Dialysis Organizations (STEPPS)
    Steven M. Brunelli, Keri L. Monda, John Mark Burkart, Matthew D. Gitlin, Peter J. Neumann, Grace S. Park, Margarita Symonian-Silver, Susan V. Yue, Brian D. Bradbury, Robert J. Rubin · 2013 · American Journal of Kidney Diseases
  96. Clinical Outcomes With Use of Erythropoiesis Stimulating Agents in Patients With the HeartMate II Left Ventricular Assist Device
    Michael E. Nassif, Jayendrakumar S. Patel, Jerrica E. Shuster, David S. Raymer, Ronald Jackups, Eric L. Novak, Brian F. Gage, Sunil M Prasad, Scott Silvestry, Gregory Alan Ewald et al. · 2015 · JACC Heart Failure
  97. Treatment with erythropoiesis-stimulating agents in chronic kidney disease patients with cancer
    Azzour D. Hazzan, Hitesh H. Shah, Susana Hong, Vipulbhai Sakhiya, Rimda Wanchoo, Steven N. Fishbane · 2014 · Kidney International
  98. Evaluation of dilution and normalization strategies to correct for urinary output in HPLC-HRTOFMS metabolomics
    GCKD Study Investigators, Franziska C. Vogl, Sebastian Mehrl, Leonhard Heizinger, Inga Schlecht, Helena U. Zacharias, Lisa Ellmann, Nadine Nürnberger, Wolfram Gronwald, Michael Fred Leitzmann et al. · 2016 · Analytical and Bioanalytical Chemistry
  99. Measurement properties of the Short Form-36 (SF-36) and the Functional Assessment of Cancer Therapy - Anemia (FACT-An) in patients with anemia associated with chronic kidney disease
    Fredric O. Finkelstein, Floortje E. van Nooten, Ingela E Wiklund, Dylan Trundell, David F Cella · 2018 · Health and Quality of Life Outcomes
  100. Sotatercept Safety and Effects on Hemoglobin, Bone, and Vascular Calcification
    Daniel W. Coyne, Hem N. Singh, William T. Smith, Ana Carolina Giuseppi, Jamie N. Connarn, Matthew Leigh Sherman, Frank Dellanna, Hartmut Horst Malluche, Keith A. Hruska · 2019 · Kidney International Reports